Boosting the production of a protein called myotubularin-related protein 7 (MTMR7) reversed signs of pulmonary arterial hypertension (PAH) in a mouse model of the disease, a study shows. MTMR7 suppresses the excess growth and migration of cells lining the arteries, which contribute to the narrowing of these blood vessels…
Inhibiting an enzyme known as Aurora kinase B (AURKB) significantly improves multiple measures of blood flow in rat models of pulmonary arterial hypertension (PAH), a study suggests. AURKB blockade worked by suppressing the excessive growth of blood vessel muscle cells, which contributes to the narrowing of pulmonary arteries that…
Cereno Scientific‘s investigational oral therapy CS1 improves right heart function in people with pulmonary arterial hypertension (PAH), according to new data from a Phase 2a clinical trial. Three months of treatment also boosted quality of life, while symptoms associated with heart failure and the risk of clinical worsening…
Lungpacer Medical’s AeroNova diaphragm neurostimulation system significantly reduced pulmonary hypertension (PH) among critically ill patients with lung failure while they were on mechanical ventilation, according to data from the STIMULUS trial. The device, which electrically stimulates nerves to activate the diaphragm muscles in synchrony with mechanical ventilation, also…
Blocking GLS1, an enzyme that drives pro-inflammatory immune macrophages, reduces the signs and symptoms of pulmonary arterial hypertension (PAH) in rats, a study reports. “This study offers a fresh outlook upon understanding the role of macrophages in PAH and provides experimental evidence in developing targeted therapeutic strategies,” the researchers…
Anoikis, a form of programmed cell death, is involved in the development of chronic thromboembolic pulmonary hypertension (CTEPH), according to a genetic analysis study. Researchers identified two anoikis-related genes associated with CTEPH — PLAUR and HMOX1 — which may serve as diagnostic biomarkers or as…
Men with pulmonary arterial hypertension (PAH) have a larger right heart size and worse survival rates than women, independent of body size and functional status, a study reports. Moreover, sex-specific mortality risk thresholds, with higher risk indicated by a larger area of the right pulmonary artery, as measured by…
The dosing regimen for Winrevair (sotatercept-csrk) is optimal for balancing efficacy and safety in adults with pulmonary arterial hypertension (PAH), an analysis of clinical trial data shows. This regimen is “well-justified based on the totality of the observed safety and efficacy data from Phase 2 and Phase 3…
Cereno Scientific said it has enrolled nine additional people with pulmonary arterial hypertension (PAH) in its expanded access program (EAP) for investigational therapy CS1, bringing the total number of patients in the program to 10. The patients will continue receiving CS1 after completing a Phase 2a clinical trial.
Lung tissue and cells from the blood vessels that pass through the lungs derived from people with pulmonary arterial hypertension (PAH) produced fewer vitamin D receptors (VDRs) than normal, a study shows. Treating PAH patient-derived blood vessel cells with calcitriol, the active form of vitamin D, reduced VDR deficiency…
LungFit PH, Beyond Air’s device for administering nitric oxide therapy, has received European CE mark approval for persistent pulmonary hypertension in newborns (PPHN). This approval allows the company to market the device in the European Union and all other countries that recognize this certification, and also extends its…
Winrevair (sotatercept-csrk) significantly reduced the risk of all-cause death, a lung transplant, or hospitalization among adults with pulmonary arterial hypertension (PAH) at a high risk of dying enrolled in a Phase 3 clinical trial. These top-line findings in the ongoing ZENITH trial (NCT04896008), testing the Merck…
Get regular updates to your inbox.